Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

Drug identity has not yet been verified against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaNCT05022901DCTHPhase 3Active not recruiting2024-03-01Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.